Please login to the form below

Not currently logged in
Email:
Password:

Boehringer to buy Amgen's California facility

Boehringer Ingelheim is to purchase the rights to all assets at Amgen's development and manufacturing facility in Fremont, California

Boehringer Ingelheim is to purchase the rights to all assets at Amgen's development and manufacturing facility in Fremont, California.

The deal will go through by the end of March, 2011, with Germany-based pharma company Boehringer taking control of the biotech's plant and workforce of 360 employees. The plant was obtained by Amgen following its acquisition of biopharma Abgenix in 2006.

Financial details of Boehringer's takeover were not disclosed.

"With great enthusiasm, we look forward to welcoming the Amgen Fremont employees into the Boehringer Ingelheim family of companies," said Professor Dr Wolfram Carius, Boehringer Ingelheim board of managing directors. "The technological expertise at Fremont and the state-of-the-art facility will enable us to further strengthen our global contract manufacturing business including new biological entity process development and manufacturing efforts."

Boehringer has had a relationship with Amgen for more than 10 years, acting as a contract manufacturer for products developed by Amgen.

Dr Fabrizio Bonanni, executive vice president of operations, Amgen, said: "We look forward to continuing to work closely with [Boehringer] to support Amgen's delivery of safe and effective medicines to patients around the world."

19th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics